From CCO: IL28B in Hepatitis C management Also HCV patients using current standard of care vs protease inhibitor–based regimens

Check It Out:
The public is welcome to view these slide presentations at Clinical Care Options
**Free Registration Required.


Debating Key Concepts in HCV Management With New HCV Therapies

Slideset: Debating Key Concepts in HCV Management With New HCV Therapies

Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss the disease burden of hepatitis C and limitations of currently available therapy
Assess how treatment with protease inhibitors will change the standard of care for treatment-naive HCV patients
Compare strategies for retreatment of treatment-experienced HCV patients using current standard of care vs protease inhibitor–based regimens
Evaluate the utility of predictors of response such as IL28B in HCV management
Recognize the adverse effects associated with the use of protease inhibitors for the treatment of HCV
.
Source: Debating Key Concepts in HCV Management With New HCV Therapies
In this Downloadable Slideset, expert faculty members provide an overview of key management strategies for new HCV agents in frontline and treatment-experienced settings.
Format: Microsoft PowerPoint (.ppt) File size: 1.97 MB Date posted: 12/3/2010
Users are encouraged to use these slides in their own presentations, but we ask that content and attribution not be changed. Users are asked to honor this intent. These slides may not be published or posted online without permission from Clinical Care Options.

***********Free Registration Required
.
Also See:
AASLD : The Liver Meeting
"The Best of The Liver Meeting®State-of-the-Art-Lectures"
presentation's in a multimedia format
AASLD 2010 Summary Of Hepatitis C Oral Inhibitors
Audio:AASLD Viral Hepatitis:Confronting a Silent Epidemic 2010
AUDIO AASLD:Hepatitis C/HBV/PIs Boceprevir/Telaprevir/
Hepatitis C Treatment 2010/2011/telaprevir,boceprevir/ Video
AASLD available data
_______________________